Literature DB >> 26424645

The Epigenetic Life Cycle of Epstein-Barr Virus.

Wolfgang Hammerschmidt1.   

Abstract

Ever since the discovery of Epstein-Barr virus (EBV) more than 50 years ago, this virus has been studied for its capacity to readily establish a latent infection, which is the prominent hallmark of this member of the herpesvirus family. EBV has become an important model for many aspects of herpesviral latency, but the molecular steps and mechanisms that lead to and promote viral latency have only emerged recently. It now appears that the virus exploits diverse facets of epigenetic gene regulation in the cellular host to establish a latent infection. Most viral genes are transcriptionally repressed, and viral chromatin is densely compacted during EBV's latent phase, but latent infection is not a dead end. In order to escape from this phase, epigenetic silencing must be reverted efficiently and quickly. It appears that EBV has perfected a clever strategy to overcome transcriptional repression of its many lytic genes to initiate virus de novo synthesis within a few hours after induction of its lytic cycle. This review tries to summarize the known molecular mechanisms, the current models, concepts, and ideas underlying this viral strategy. This review also attempts to identify and address gaps in our current understanding of EBV's epigenetic mechanisms within the infected cellular host.

Entities:  

Keywords:  DNA methylation; Epigenetics; Pioneer factor; Reprogramming; Transcription

Mesh:

Year:  2015        PMID: 26424645     DOI: 10.1007/978-3-319-22822-8_6

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  20 in total

1.  Coordinate Regulation of TET2 and EBNA2 Controls the DNA Methylation State of Latent Epstein-Barr Virus.

Authors:  Fang Lu; Andreas Wiedmer; Kayla A Martin; Priyankara J M S Wickramasinghe; Andrew V Kossenkov; Paul M Lieberman
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 2.  Epstein-Barr virus: a master epigenetic manipulator.

Authors:  Rona S Scott
Journal:  Curr Opin Virol       Date:  2017-08-04       Impact factor: 7.090

3.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 4.  Epigenetics and Genetics of Viral Latency.

Authors:  Paul M Lieberman
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

5.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

6.  Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.

Authors:  Kayla A Martin; Lena N Lupey; Italo Tempera
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 7.  Epigenetic crossroads of the Epstein-Barr virus B-cell relationship.

Authors:  Thomas C Frost; Benjamin E Gewurz
Journal:  Curr Opin Virol       Date:  2018-09-15       Impact factor: 7.090

8.  Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.

Authors:  Samantha S Soldan; Chenhe Su; R Jason Lamontagne; Nicholas Grams; Fang Lu; Yue Zhang; James D Gesualdi; Drew M Frase; Lois E Tolvinski; Kayla Martin; Troy E Messick; Jonathan T Fingerut; Ekaterina Koltsova; Andrew Kossenkov; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2021-06-09       Impact factor: 6.823

9.  PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.

Authors:  Lena N Lupey-Green; Stephanie A Moquin; Kayla A Martin; Shane M McDevitt; Michael Hulse; Lisa B Caruso; Richard T Pomerantz; Jj L Miranda; Italo Tempera
Journal:  Virology       Date:  2017-04-26       Impact factor: 3.616

10.  Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.

Authors:  Lianne J N Kraal; Marieke L Nijland; Kristine L Germar; Dominique L P Baeten; Ineke J M Ten Berge; Cynthia M Fehres
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.